Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis

← catalyst calendar

NCT04036435

Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.

Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
1,466actual
Sites
302
Countries
Australia, Canada, China +17

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2019-08-12actualWhen the study began enrolling
Primary completion2026-07-25estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completion2026-07-26estimatedThe whole study's end, after follow-up
First posted2019-07-29actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2025-10-20actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Psoriasis

Interventions

  • Drug: BMS-986165 — also filed as Deucravacitinib
  • Drug: Placebo

Primary outcomes

what the primary-completion date above is the date OF
Incidence of Adverse Events (AEs)
measured Up to 244 weeks
Incidence of Serious Adverse Events (SAEs)
measured Up to 244 weeks
Proportion of participants achieving a satisfactory humoral response: pneumococcus
measured At Week 4 post vaccination
Proportion of participants achieving a satisfactory humoral response: tetanus titers
measured At Week 4 post vaccination

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed